Department of Pharmacology, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke, QC J1H 5 N4, Canada.
Mol Neurodegener. 2012 Jun 26;7:31. doi: 10.1186/1750-1326-7-31.
The Aβ peptide that accumulates in Alzheimer's disease (AD) is derived from amyloid precursor protein (APP) following proteolysis by β- and γ-secretases. Substantial evidence indicates that alterations in APP trafficking within the secretory and endocytic pathways directly impact the interaction of APP with these secretases and subsequent Aβ production. Various members of the low-density lipoprotein receptor (LDLR) family have been reported to play a role in APP trafficking and processing and are important risk factors in AD. We recently characterized a distinct member of the LDLR family called LDLR-related protein 10 (LRP10) that shuttles between the trans-Golgi Network (TGN), plasma membrane (PM), and endosomes. Here we investigated whether LRP10 participates in APP intracellular trafficking and Aβ production.
In this report, we provide evidence that LRP10 is a functional APP receptor involved in APP trafficking and processing. LRP10 interacts directly with the ectodomain of APP and colocalizes with APP at the TGN. Increased expression of LRP10 in human neuroblastoma SH-SY5Y cells induces the accumulation of mature APP in the Golgi and reduces its presence at the cell surface and its processing into Aβ, while knockdown of LRP10 expression increases Aβ production. Mutations of key motifs responsible for the recycling of LRP10 to the TGN results in the aberrant redistribution of APP with LRP10 to early endosomes and a concomitant increase in APP β-cleavage into Aβ. Furthermore, expression of LRP10 is significantly lower in the post-mortem brain tissues of AD patients, supporting a possible role for LRP10 in AD.
The present study identified LRP10 as a novel APP sorting receptor that protects APP from amyloidogenic processing, suggesting that a decrease in LRP10 function may contribute to the pathogenesis of Alzheimer's disease.
阿尔茨海默病(AD)中积累的 Aβ 肽是通过β-和γ-分泌酶对淀粉样前体蛋白(APP)的水解产生的。大量证据表明,APP 在分泌和内吞途径中的运输变化直接影响 APP 与这些分泌酶的相互作用以及随后的 Aβ 产生。低密脂蛋白受体(LDLR)家族的各种成员已被报道在 APP 运输和加工中发挥作用,并且是 AD 的重要危险因素。我们最近描述了 LDLR 家族的一个独特成员 LDLR 相关蛋白 10(LRP10),它在高尔基网络(TGN)、质膜(PM)和内体之间穿梭。在这里,我们研究了 LRP10 是否参与 APP 细胞内运输和 Aβ 产生。
在本报告中,我们提供的证据表明,LRP10 是一种功能性 APP 受体,参与 APP 的运输和加工。LRP10 与 APP 的细胞外结构域直接相互作用,并在 TGN 处与 APP 共定位。LRP10 在人神经母细胞瘤 SH-SY5Y 细胞中的表达增加会导致成熟 APP 在高尔基体中的积累,并减少其在细胞表面的存在及其加工成 Aβ,而 LRP10 表达的下调会增加 Aβ 的产生。负责 LRP10 向 TGN 循环的关键基序的突变导致 APP 与 LRP10 异常重新分布到早期内体,并伴有 APPβ-裂解成 Aβ 的增加。此外,AD 患者死后脑组织中 LRP10 的表达明显降低,支持 LRP10 在 AD 中的可能作用。
本研究确定了 LRP10 作为一种新型的 APP 分拣受体,可防止 APP 发生淀粉样变性加工,提示 LRP10 功能的降低可能导致阿尔茨海默病的发病机制。